BioVie Inc. Announces Reverse Stock Split

Core Points - BioVie Inc. has executed a reverse stock split of its Class A common stock at a ratio of 1-for-10, effective immediately [1][2] - The company's common stock will continue to trade on The Nasdaq Capital Market under the symbol "BIVI" with a new CUSIP number of 09074F405 [1] Company Overview - BioVie Inc. is a clinical-stage company focused on developing innovative drug therapies for neurological and neurodegenerative disorders, as well as advanced liver disease [3] - The drug candidate bezisterim targets neuroinflammation and insulin resistance, which are associated with Alzheimer's disease (AD) and Parkinson's disease (PD) [3] - The orphan drug candidate BIV201, which has received FDA Fast Track status, is being evaluated for the treatment of ascites due to chronic liver cirrhosis [3] - BIV201 is already approved in the U.S. and approximately 40 other countries for related complications of advanced liver cirrhosis [3]